Swedish private-equity firm EQT said that together with its co-shareholders it has agreed to sell Ellab to Novo Holdings.
Headquartered in Hillerod, Denmark, Ellab provides validation and monitoring solutions and services for biotech and pharmaceutical processes.
EQT said it invested in the company in 2019 and since then Ellab has tripled its revenue, earnings before interest, tax, depreciation and amortization and number of employees, while experiencing around 20% annual organic revenue growth and completing 15 add-on acquisitions.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
The sale to Novo Holdings is expected to close in the third quarter, subject to regulatory approval.
Novo Holdings is a holding and investment company responsible for managing the assets and the wealth of the Novo Nordisk Foundation. Wholly-owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novozymes.
Source: Market Watch
Can’t stop reading? Read more
University of Utah set to seal $500m private equity venture with Otro Capital
University of Utah set to seal $500m private equity venture with Otro Capital Otro Capital is...
Apollo and Capital Power launch $3bn partnership to buy US gas plants
Apollo and Capital Power launch $3bn partnership to buy US gas plants Apollo Global Management has...
Luxury jeweller APM Monaco could fetch $2bn as TPG explores sale or IPO
Luxury jeweller APM Monaco could fetch $2bn as TPG explores sale or IPO TPG is weighing strategic...